Why Eli Lilly's Stock Could Be Gearing Up for a Big Rally

Key Points If it obtains regulatory approval for its GLP-1 pill, that would be a huge catalyst ahead. The company already has injectable GLP-1 drugs that are generating billions in revenue, Despite its valuation, the stock only appears expensive when you look at the short term. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) shares have been disappointing to own this year. As of the end of last week, they were down more than 4% since the start of the year. But this has still been a ...